POLARIS · Canada

What is the efficacy and safety of tirzepatide for glycemic control and weight loss in adults with type 2 diabetes?

100%of claims verified4 verified sections · every sentence traces to its cited source span
Two-family invariant verifiedSignature missing
bundle_real_tirzepatide_0001deepseek/deepseek-v4-proWed, 20 May 2026 00:00:00 GMT
Full manifest
Bundle ID
bundle_real_tirzepatide_0001
Schema version
v1.0
POLARIS version
1.0.0
Generator model
deepseek/deepseek-v4-pro
Decision ID
decision_real_tirzepatide_0001
Pool ID
pool_real_tirzepatide_0001
Report ID
report_real_tirzepatide_0001
Created (UTC)
Wed, 20 May 2026 00:00:00 GMT

Efficacy

Safety

Comparative

Long-term Outcomes

The estimated treatment differences were −0.15 percentage points (95% CI −0.28 to −0.03), −0.39 percentage points (95% CI −0.51 to −0.26), and −0.45 percentage points (95% CI −0.57 to −0.32), all favoring tirzepatide .

Verified
at a dose of 5 mg, 10 mg, and 15 mg were −2.01 percentage points, −2.24 percentage points, and −2.30 percentage points, respectively, as compared with −1.86 percentage points with semaglutide (Figure 1A). All tirzepatide doses were found to be superior to semaglutide, with estimated treatment differences of −0.15 percentage points (95% confidence interval [CI], −0.28 to −0.03; P=0.02) with tirzepatide 5 mg, −0.39 percentage points (95% CI, −0.51 to −0.26; P<0.001) with tirzepatide 10 mg, and −0.45 percentage points (95% CI, −0.57 to −0.32; P<0.001) with tirzepatide 15 mg. The glycated hemoglobin level over time is shown in (Figure 1B). A total of 82 to 86% of the